Shield Therapeutics

David, Andy and Santosh will be attending BIO-Europe in Lisbon, Portugal from 23-25 March 2026. Our key focus is in-licensing, and we still have a few meeting slots available. If you’re attending and would like to connect via partnering, feel free to reach out.

We've just released the following announcement: Chinese NMPA Accepts MAA Submission for ACCRUFeR® (ferric maltol) Check out the full announcement and join in with the conversation at: shieldtherapeutics.com/announcements/… #STX

We've just released the following announcement: Shield Therapeutics - Total Voting Rights Check out the full announcement and join in with the conversation at: shieldtherapeutics.com/announcements/… #STX

As we celebrate the Lunar New Year, we recognise a time of renewal, reflection, and forward momentum. Wishing all who celebrate a prosperous and successful Lunar New Year. shieldtherapeutics.com/partnerships

We are excited to officially welcome our new joiners! At Shield, we believe our people are our greatest strength, so welcome aboard, we are so glad you’re here, and we are excited for what 2026 holds together. shieldtherapeutics.com

Elizabeth joined Shield in January 2025 and is a senior global regulatory affairs leader with nearly 20 years of experience across biosimilars and innovative medicines. Please join me in welcoming Elizabeth to the team.

At Shield Therapeutics, our team are committed to improving the lives of our patients suffering with iron deficiency, with or without anemia and to making a meaningful difference to their everyday lives. Visit shieldtherapeutics.com for more information.

Shield Therapeutics announces that the US Food and Drug Administration (FDA) has granted to Shield an additional 3 years of Data Exclusivity for ACCRUFeR® (ferric maltol). For full details visit shieldtherapeutics.com

Shield Therapeutics announces that its partner in China, ASK, expects to submit the file for marketing authorisation to the China National Medical Products Administration for the approval for ACCRUFeR® in China in Q1 2026. shieldtherapeutics.com

Shield Therapeutics announces that, in line with the Company’s guidance, Shield has achieved positive operating cash flow in Q4 2025 and provides an unaudited full year trading update for the year ended 31 December 2025 (“FY25”). shieldtherapeutics.com

Following a priority review of the clinical supplement, the US Food and Drug Administration (FDA) has approved the extension of the indication for ACCRUFeR® (ferric maltol) to include adolescents. For more details visit shieldtherapeutics.com.

Shield Therapeutics announces the amendment of its senior term debt financing. This strategic financial update, strengthens the Company's financial position by lowering debt related costs and provides flexibility to drive further growth and explore suitable M&A opportunities.

This Thanksgiving, we are taking a moment to reflect on what matters most. To our patients and partners, thank you for allowing us to be part of your journey. From everyone at Shield, we wish you a wonderful Thanksgiving. 🍁

Shield Therapeutics today announced that its partner, MEDLEAP Pharma has initiated a Phase II clinical trial for ACCRUFeR® (ferric maltol), a new drug candidate for Pulmonary Arterial Hypertension (PAH), for patients in Japan. For full details visit shieldtherapeutics.com/news/

ACCRUFeR® Pediatric Pharmacokinetic Results will be Presented at the American Society of Hematology (ASH) Conference. Results from PK Sub study of Positive Phase 3 Pediatric Trial confirmed suitability for iron replacement in children 1 month and above. shieldtherapeutics.com/news/

Shield Therapeutics plc is pleased to announce that the Korean Ministry of Food and Drug Safety has granted regulatory approval for ACCRUFeR® in the Republic of Korea for the treatment of iron deficiency in adult subjects. For full details visit shieldtherapeutics.com/news/

The Shield team had a great experience at BIO-Europe 2025. It was a pleasure connecting with so many industry professionals and exploring new opportunities for collaboration. A big thank you to everyone we met, we look forward to staying in touch and continuing the conversations.

We are looking forward to attending #BIOEurope! Join Shield Therapeutics in Vienna, Austria, November 3–5, 2025 or connect with the team via partnering. We look forward to seeing you there.

We are excited to be exhibiting at #AAFPFMX, October 5–9 in Anaheim, CA. Visit us at Booth 1683 to see how Shield Therapeutics is supporting family physicians on the frontlines of care. 👉 Learn more and register: i.snoball.it/p/iZ4HF/l